Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent
- 4 March 2008
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (7), 2302-2306
- https://doi.org/10.1021/jm701199p
Abstract
In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor 15d (LY2109761) is representative of a novel series of antitumor agents.Keywords
This publication has 20 references indexed in Scilit:
- Antiangiogenic therapy in cancerDrugs of the Future, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)Journal of Medicinal Chemistry, 2002
- TGF-β signaling in cancer – a double-edged swordTrends in Cell Biology, 2001
- TGF-β signaling in tumor suppression and cancer progressionNature Genetics, 2001
- TGFβ Signaling in Growth Control, Cancer, and Heritable DisordersCell, 2000
- Role of Transforming Growth Factor-beta Signaling in CancerJNCI Journal of the National Cancer Institute, 2000
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapyTrends in Pharmacological Sciences, 1995
- Anti-AngiogenesisAnnals of Surgery, 1972